Article Text

Download PDFPDF
Graves’ disease following administration of second dose of SARS-CoV-2 vaccine
  1. Timothy James Goblirsch1,
  2. Ambika E Paulson1,
  3. Gerti Tashko2 and
  4. Asefa Jejaw Mekonnen3
  1. 1Medicine, Georgetown University School of Medicine, Washington, DC, USA
  2. 2Endocrinology, GT Health, Rockville, Maryland, USA
  3. 3Sleep Medicine, Rockville Internal Medicine Group, Rockville, Maryland, USA
  1. Correspondence to Timothy James Goblirsch; tjg58{at}


The SARS-CoV-2 vaccines have had an overwhelming success in curbing the COVID-19 global pandemic, accounting for countless lives saved. Adverse reactions are inevitable, given the vast scale of vaccination required to mitigate future surges of COVID-19. Hyperthyroid disorders have been reported as potential adverse reactions to SARS-CoV-2 vaccines in two patients with Graves’ disease and a group of adults with subacute thyroiditis occurring in young women healthcare workers. We report a case of clinical Graves’ disease in a woman with a previously stable multinodular goitre that occurred 14 days following her second dose of Pfizer-BioNTech SARS-CoV-2 vaccine.

  • COVID-19
  • thyroid disease
  • unwanted effects/adverse reactions
  • thyrotoxicosis

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors All authors: contributed equally to the case report, data analysis and interpretation of data. TJG, AEP and AJM: planning, conception and design and data acquisition. AJM: cared for the patient. GT: critically reviewed the case report.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.